AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to ...

ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.

AbbVie's Skyrizi and Rinvoq are rapidly growing, offsetting Humira's revenue decline. Read why ABBV presents a strong ...

American pharmaceutical giant AbbVie ($ABBV) abruptly lowered its Q3 and full year Fiscal 2024 earnings expectations owing to ...

Among the larger deals, AbbVie acquired ImmunoGen, which added antibody-drug conjugate Elahere, and Cerevel Therapeutics ... today’s Zacks #1 Rank (Strong Buy) stocks here.

We recently published a list of 8 Best Inexpensive Stocks To Invest In Now. In this article, we are going to take a look at ...

The healthcare industry is set for growth due to the growing demand for quality healthcare services and ongoing advancements ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?